A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa therapy (RESTORE)
Brief description of study
This is a clinical study of patients with symptomatic neurogenic orthostatic hypotension, who have been diagnosed with Parkinson's Disease,Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) deficiency to assess sustained effects of droxidopa therapy.
Detailed description of study
If you agree to participate in this study and have given your consent, your total study participation could last up to approximately 36 weeks. The study is made up of three main periods: Open-Label Dose Titration, Open-Label Treatment, and Double Blind Treatment. There will be one Safety Follow-Up Visit.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Hypotension,Orthostatic Hypotension,Parkinson's disease,parkinson's disease,autonomic neuropathies,Autonomic neuropathy NOS,neuropathy autonomic,Autonomic neuropathy (disorder),Autonomic neuropathy
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
07 Oct 2019.
Study ID: 824386
